Latest Information Update: 02 Oct 2001
At a glance
- Originator Fujisawa
- Class Antiasthmatics
- Mechanism of Action Leukotriene receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 02 Oct 2001 No-Development-Reported for Asthma in Japan (Unknown route)
- 16 Sep 1998 New profile
- 16 Sep 1998 Phase-II clinical trials for Asthma in Japan (Unknown route)